Evidence map›Paper›PMID 40558442›Full record

ReviewBiosensors2025

CRISPR/Cas12a-Based Biosensing: Advances in Mechanisms and Applications for Nucleic Acid Detection.

Kun Du, Qinlong Zeng, Mingjun Jiang, Zhiqing Hu, Miaojin Zhou, Kun Xia

Abstract readReview
In one paragraph

Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kun DuMOE Key Laboratory of Rare Pediatric Diseases, College of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang 421009, China.ORCID 0009-0007-2040-0473
Qinlong ZengInnovation Center for Diagnostics and Treatment of Thalassemia, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Mingjun JiangThe Second Affiliated Hospital, Department of Vascular Surgery, Hengyang Medical School, University of South China, Hengyang 421099, China.ORCID 0000-0003-1417-360X
Zhiqing HuMOE Key Laboratory of Rare Pediatric Diseases, College of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang 421009, China.
Miaojin ZhouMOE Key Laboratory of Rare Pediatric Diseases, College of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang 421009, China.ORCID 0000-0002-6636-6000
Kun XiaMOE Key Laboratory of Rare Pediatric Diseases, College of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang 421009, China.

Funding

National Natural Science Foundation of China No. 82130043National Natural Science Foundation of China No. 82330035National Natural Science Foundation of China No. 82361138573National Natural Science Foundation of Hunan Province No. 2021SK1010Natural Science Foundation of Hunan Province No. 2024JJ5340Science and Technology innovation Program of Hunan Province No. 2024RC3207Scientific Research Fund of Hunan Provincial Education Department No. 23B0437
6 · The paper itself

Abstract

Nucleic acid detection technology is crucial for molecular diagnosis. The advent of CRISPR/Cas12a-based nucleic acid detection has considerably broadened its scope, from the identification of infectious disease-causing microorganisms to the detection of disease-associated biomarkers. This innovative system capitalizes on the non-specific single-strand cleavage activity of Cas12a upon target DNA recognition. By employing a fluorescent probe in the form of a single-stranded DNA/RNA, this technology enables the observation of fluorescence changes resulting from nonspecific cleavage, thereby facilitating detection. CRISPR/Cas12a-based detection systems can be regarded as a new type of biosensor, offering a practical and efficient approach for nucleic acid analysis in various diagnostic settings. CRISPR/Cas12a-based biosensors outperform conventional nucleic acid detection methods in terms of portability, simplicity, speed, and efficiency. In this review, we elucidate the detection principle of CRISPR/Cas12a-based biosensors and their application in disease diagnostics and discuss recent innovations and technological challenges, aiming to provide insights for the research and further development of CRISPR/Cas12a-based biosensors in personalized medicine. Our findings show that although CRISPR/Cas12a-based biosensors have considerable potential for various applications and theoretical research, certain challenges remain. These include simplifying the reaction process, enhancing precision, broadening the scope of disease detection, and facilitating the translation of research findings into clinical practice. We anticipate that ongoing advancements in CRISPR/Cas12a-based biosensors will address these challenges.

Indexed as

Biosensing TechniquesCRISPR-Cas SystemsNucleic AcidsDNAHumansDNANucleic AcidsCRISPR/Cas12a-based biosensorsisothermal amplificationnucleic acid detectionuniversal screening

Identifiers

PMID40558442
PMCPMC12190445

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.